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Abstract PSP-I/PSP-II, a heterodimer of glycosylated sper-
madhesins, is the major component of boar seminal plasma.
Similarly to other spermadhesins, the PSP-II subunit is a lectin
which displays heparin- and zona pellucida glycoprotein-binding
activities. We have investigated the ligand binding capabilities
of the heterodimer and the isolated subunits using several
polysaccharides, glycoproteins, and phospholipids. PSP-II binds
the sulfated polysaccharides heparin and fucoidan in a dose-
dependent and seemingly-specific manner. In addition, PSP-II
binds oligosaccharides containing exposed mannose-6-phos-
phate monoester groups and the binding is selectively inhibited
by mannose-6-phosphate and glucose-6-phosphate. Inhibition
experiments indicate that binding of PSP-II to sulfated
polysaccharides and mannose-6-phosphate-containing oligosac-
charides involves distinct but possibly overlapping binding sites.
Heterodimer formation with PSP-I abolishes both the heparin
and the mannose-6-phosphate binding capabilities, suggesting
that the corresponding sites may be located at the dimer
interface. Using the crystal structure of PSP-I/PSP-II hetero-
dimer as a template, we have explored possible binding sites
which satisfy the observed binding characteristics. In the
proposed models, PSP-II Arg43 appears to play a pivotal role
in both heparin- and mannose-6-phosphate-complexation as well
as in heterodimer formation.
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1. Introduction
The seminal plasma, the £uid in which mammalian sperma-
tozoa are suspended in semen, is a complex mixture of secre-
tions originating from the epididymis and the male accessory
reproductive organs. The protein composition of seminal plas-
mas varies from species to species but reports from several
mammalian species indicate that seminal plasma contains fac-
tors that in£uence both the fertilising ability of spermatozoa
and exert important e¡ects on the female reproductive phys-
iology [1^3]. In the pig, the bulk of seminal plasma proteins
belong to the spermadhesin family [4,5]. Spermadhesins, a
group of 12^16-kDa proteins, emerge as a novel protein fam-
ily of animal lectins, which coat to the sperm surface at ejac-
ulation and are believed to play major roles in sperm capaci-
tation and gamete interaction (reviewed in [6^8]).
Besides the porcine, spermadhesin molecules have been so
far identi¢ed in bull and stallion [9,10]. Sequence variation,
glycosylation and the aggregation state of spermadhesins ap-
pear to modulate their sperm-coating and carbohydrate-rec-
ognition capabilities [11,12]. Thus, aSFP, a monomeric non-
glycosylated bovine spermadhesin, shares over 50% amino
acid sequence identity with its stallion and boar counterparts
but neither binds to the sperm surface nor possesses lectin
activity [9]. On the other hand, glycosylation of the conserved
asparagine-50 abolishes the carbohydrate-binding activity of
boar spermadhesins [11].
Porcine seminal plasma glycoproteins I (PSP-I) and II
(PSP-II) are major components of seminal plasma which
form non-covalent heterodimers [12]. The PSP-I/PSP-II heter-
odimer displays carbohydrate-binding activity linked to the
PSP-II subunit [12]. The PSP-I/PSP-II complex does not
bind to the sperm surface excluding a role in gamete interac-
tion. Nonetheless, lectin-glycoconjugate recognition systems
play a central role in other aspects of mammalian reproduc-
tive physiology, e.g. sperm-epithelial cell interactions leading
to sperm capacitation during residence in the female’s repro-
ductive tract [1^3]. Glycobiological interactions in the sow’s
uterus mediated by non-sperm-binding boar seminal plasma
lectins deserve further investigations.
The aim of this study was to investigate the binding specif-
icities of spermadhesin PSP-I/PSP-II. PSP-II but not the PSP-
I/PSP-II heterodimer speci¢cally binds sulfated polysaccha-
rides and mannose-6-phosphate-containing oligosaccharides
at distinct but possibly interrelated binding sites. Docking of
Man-6-P and of a tetrasaccharide fragment of heparin onto
the crystal structure of the PSP-II subunit suggests possible
binding sites for these ligands.
2. Methods
2.1. Isolation and radioiodination of proteins
The PSP-I/PSP-II heterodimer was isolated from the non-heparin-
binding fraction of boar seminal plasma by gel ¢ltration chromatog-
raphy, and its subunits were puri¢ed from the heterodimer by re-
versed-phase HPLC [12]. Proteins (300 Wg each) were labelled with
0.2 mCi of 125I using Iodogen (Pierce) according to the manufacturers’
recommendations. The radioiodinated proteins were indistinguishable
from the corresponding unlabelled proteins by SDS-PAGE and auto-
radiography. The reassociation capability of isolated PSP-I and PSP-
II was assessed by gel ¢ltration of equimolar mixtures of the proteins
using a Superose 12 HR 10/30 column (Pharmacia Biotech) equili-
brated in 10 mM Tris-HCl, pH 7.8, 0.15 M NaCl (TBS). The £ow
rate was 0.5 ml/min and the elution was monitored at 280 nm. Con-
trol proteins were chromatographed under similar conditions.
2.2. Binding of 125I-PSP-II to PSP-I-Sepharose
PSP-I was coupled to cyanogen bromide-activated Sepharose 4B
(Pharmacia Biotech) according to the manufacturers’ instructions, ex-
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cept that prior to the coupling step the gel was treated with 0.1 M
HCl for 1 h at 25‡C to reduce non-speci¢c binding [13]. Aliquots of
sedimented PSP-I-Sepharose (13.3 mg of PSP-I/ml gel) were resus-
pended in polypropylene microcentrifuge tubes to a ¢nal volume of
0.5 ml with TBS and incubated with 10 Wl (35 000 cpm) of 125I-PSP-II
solution. After 2 h at 25‡C with occasional shaking, each sample was
centrifuged and the radioactivity of the supernatant solution was
counted in an LKB Mini-gamma counter. Non-speci¢c binding or
trapping on the Sepharose beads was estimated in parallel experiments
using unsubstituted Sepharose 6B (Pharmacia Biotech).
2.3. Microwell binding assays
The following ligands were tested: (i) the polysaccharides: heparin;
fucoidan (an algal polysaccharide containing fucose sulfate); zymosan
A, a Saccharomyces cerevisiae cell wall polysaccharide preparation
containing mannan and phosphomannan polymers [14] ; the glycos-
aminoglycan chondroitin-6-sulfate; (ii) the glycoproteins: yeast inver-
tase, containing phosphomannosyl residues [15]; ribonuclease B (con-
taining high-mannose oligosaccharide chains); native and desialylated
(by mild acid hydrolysis or neuraminidase digestion [17]) ¢brinogen
and transferrin, each containing biantennary complex-type carbohy-
drate chains; fetuin and asialofetuin, which contain N-linked bianten-
nary and triantennary complex-type and O-linked oligosaccharide
chains; bovine seminal plasma glycoprotein PDC-109 bearing a single
O-linked trisaccharide [18]; carboxypeptidase Y (CPY) from Saccha-
romyces cerevisiae, which contains mannose-rich oligosaccharide
chains with one or two mannose-6-phosphate (Man-6-P) residues di-
esteri¢ed with mannose or mannobiose [15,16]. Mild acid hydrolysis
of glycoproteins was carried out in 50 mM H2SO4 for 90 min at 80‡C;
(iii) the lipids: cholesterol-3-sulfate; ceramide; phosphatidic acid;
sphingomyelin; phosphatidylethanolamine; phosphatidylserine; phos-
phatidylcholine; and cardiolipin.
Microtiter-plate wells (Costar) were coated with the di¡erent test
compounds as follows. (i) For polysaccharides, wells were pre-coated
with 50 Wl of poly-L-lysine (50 Wg/ml in 50 mM sodium bicarbonate
bu¡er, pH 9.6), for 16 h at 4‡C. After washing with distilled water, the
di¡erent polysaccharides were immobilised onto the wells of poly-L-
lysine-coated plates by ¢xation with 50 Wl of 0.05% glutaraldehyde in
5 mM phosphate bu¡er, pH 7.2, 0.2 M NaCl for 10 min at 20‡C. (ii)
For glycoproteins, 50 Wl of the protein solutions in TBS were added to
the wells and kept for 16 h at 4‡C. (iii) For lipids, 50 Wl of the lipid
solutions in methanol were added to the wells followed by evapora-
tion to dryness at 37‡C.
After immobilisation of the di¡erent test compounds, wells were
blocked with bovine serum albumin and binding of the 125I-labelled
proteins was assayed essentially as described [17], except that the
bu¡er was TBS. Where indicated, microtiter-plate wells coated with
acid-hydrolysed CPY (100 Wg/ml) were treated prior to the incubation
with the labelled proteins with 50 Wl of a 30-U/ml alkaline phospha-
tase solution from bovine intestinal mucosa (Sigma, type VII-S) in 0.1
M Tris-HCl, pH 9.5, 0.1 M NaCl, 50 mM MgCl2, for di¡erent periods
of time at 37‡C.
For inhibition assays, microtiter-plate wells were coated with acid-
hydrolysed CPY (100 Wg/ml) or with heparin (300 Wg/ml), and the
binding of 125I-PSP-II was measured in the absence or presence of
di¡erent concentrations of the inhibitors.
2.4. Molecular modelling
Three-dimensional X-ray crystallographic models of (a) mannose,
(b) a tetrasaccharide fragment of heparin and (c) the PSP-I/PSP-II
heterodimer (PDB accession codes, 1JPC, 1BFB and 1SPP, respec-
tively) were used. The 3D-generated molecules of Man-6-P and the
heparin tetrasaccharide were manually docked into possible sites on
PSP-II using the software program FRODO [19]. The resulting work-
ing models were subjected to stereochemical and geometrical re¢ne-
ment by energy minimisation using XPLOR [20] in order to prevent
non-allowed contacts and to ensure proper geometry. The ¢nal mod-
els were regularised with a slow cooling simulated annealing molec-
ular dynamics protocol [20].
3. Results
3.1. Isolated PSP-I and PSP-II associate into heterodimers
By gel ¢ltration chromatography, isolated PSP-I and PSP-II
glycoproteins each eluted as a single peak with apparent mo-
lecular mass of 14 kDa. When an equimolar mixture of the
two proteins was chromatographed, a single peak at the elu-
tion volume of native PSP-I/PSP-II heterodimer was obtained.
In addition, radioiodinated PSP-II bound in a concentration-
dependent manner to PSP-I immobilised onto Sepharose
beads. At subequimolar ratio, PSP-II was quantitatively re-
tained. Maximal binding was 84 þ 2% after subtracting a
background level of 16 þ 2% of non-speci¢c binding of 125I-
PSP-II to unsubstituted Sepharose. The ability of isolated
PSP-I and PSP-II to reassociate into heterodimers was taken
as a hint that the bulk of separated glycoproteins most likely
retained a conformation identical or close to their native state.
3.2. Binding studies with immobilised polysaccharides,
glycoproteins and phospholipids
125I-PSP-II bound to the immobilised sulfated polysaccha-
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Fig. 1. Binding of 125I-PSP-II to polysaccharides coated onto plastic
microwells. Polysaccharides were immobilised at di¡erent concentra-
tions onto microwells pre-coated with poly-L-lysine and binding of
125I-PSP-II was assayed as described in Section 2. Fucoidan (F) ;
heparin (E) ; zymosan A (R) ; invertase (a) ; and chondroitin-6-sul-
fate (b).
Table 1
Inhibition of binding of 125I-PSP-II to hydrolyzed CPY
Compound Maximum concentration % Inhibition IC50
Man 100 mM 42 þ 7 s 100 mM
Man-6-P 30 mM 58 þ 2 22.4 mM
GlcNAc 100 mM 0 ^
Heparin 8 mg/ml 60 þ 5 3.3 mg/ml
Fucoidan 8 mg/ml 59 þ 3 2.5 mg/ml
PSP-I 10 mg/ml 93 þ 2 0.93 mg/ml
Microtiter plate wells were coated with mild acid hydrolysed CPY (100 Wg/ml) and the binding of 125I-PSP-II was determined in the absence or
presence of di¡erent concentrations of inhibitors. Inhibition of binding (mean of at least two data points) at the maximum concentration of
inhibitor tested is shown. IC50, concentration of inhibitor producing 50% inhibition.
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rides heparin and fucoidan. The same binding activities have
been described for other members of the spermadhesin protein
family [4]. 125I-PSP-II bound to a lesser extent to the poly-
saccharide zymosan A, no binding was observed to chondroi-
tin-6-sulfate, and only trace binding to yeast invertase was
deteced (Fig. 1). Under the same conditions no binding to
any of the di¡erent polysaccharides tested was detected with
125I-PSP-I or 125I-PSP-I/PSP-II.
When di¡erent glycoproteins of de¢ned oligosaccharide
chains were tested (Fig. 2), there was no binding of 125I-
PSP-II to ribonuclease B, ¢brinogen and transferrin, whether
native or after desialylation by mild acid hydrolysis or by
neuraminidase digestion. There was neither binding to native
or desialylated fetuin, and to bovine PDC-109, and only trace
binding to CPY was detected. However, mild acid hydrolysis
of the phosphodiester bond of the CPY, yielding the phos-
phomonoester oligosaccharide [16], resulted in strong binding
of 125I-PSP-II (Fig. 2). The binding was progressively reduced
by subsequent alkaline phosphatase digestion of the hydro-
lysed glycoprotein (Fig. 2, inset), demonstrating the require-
ment of an exposed phosphate group for binding of 125I-PSP-
II to CPY. However, no binding of 125I-PSP-I or 125I-PSP-I/
PSP-II to native or mild acid hydrolysed CPY was observed
(data not shown).
None of the seminal plasma proteins showed signi¢cant
binding to cholesterol 3-sulfate, ceramide, phosphatidic acid,
phosphatidylethanolamine, phosphatidylserine, sphingomye-
lin, or cardiolipin. As a positive control, 125I-PDC-109 bound
strongly to phosphatidylcholine and to a lesser extent to
sphingomyelin as previously reported [21^23].
3.3. Inhibition of PSP-II binding to immobilised
acid-hydrolysed CPY and heparin
The speci¢city of 125I-PSP-II binding to acid-treated CPY
was explored by inhibition assays (Table 1). Among the three
monosaccharide constituents of hydrolysed CPY oligosac-
charide, Man-6-P was the most potent inhibitor of the binding
of 125I-PSP-II to the immobilised glycoligand, reaching 60%
inhibition at 30 mM ¢nal concentration. Mannose was signi¢-
cantly less inhibitory, while N-acetylglucosamine was inactive.
Heparin and fucoidan induced a dose-dependent and satura-
ble inhibition of 125I-PSP-II binding to acid-treated CPY,
reaching a maximum inhibition level of 60% (Table 1). 125I-
PSP-I was the most potent inhibitor of the binding of 125I-
PSP-II to acid-treated CPY, reaching s 90% inhibition at 0.9
mg/ml.
The speci¢city and relationship of 125I-PSP-II binding to
hydrolysed CPY and to heparin was further investigated using
di¡erent monosaccharides as inhibitors of the binding to both
glycoconjugates (Fig. 3). Man-6-P and glucose-6-phosphate
were the most potent inhibitors of the binding of 125I-PSP-II
to hydrolysed CPY (Fig. 3, left panel). Mannose-1-phosphate,
mannose, galactose-6-phosphate, galactose-6-sulfate and gal-
actose were weaker inhibitors or almost inactive. On the con-
trary, Man-6-P and glucose-6-phosphate were not inhibitory
of the binding of 125I-PSP-II to heparin (Fig. 3, right panel).
At 10 mM ¢nal concentration, these compounds even gave
rise consistently to an apparent enhancement of the binding
of 125I-PSP-II to heparin. Mannose and galactose produced
weak inhibition of the interaction of 125I-PSP-II with heparin,
while galactose-6-phosphate, galactose-6-sulfate and man-
nose-1-phosphate were the most potent inhibitors.
3.4. Docking of Man-6-P and heparin tetrasaccharide
onto PSP-II
No three-dimensional structure of a lectin/Man-6-P com-
plex is available. However, guided by the known basic fea-
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Fig. 3. Inhibition of the binding of 125I-PSP-II to hydrolysed CPY
(left panel) and to heparin (right panel). Hydrolysed CPY (100 Wg/
ml and heparin (300 Wg/ml) were immobilised onto plastic micro-
wells and the binding of 125I-PSP-II was determined in the absence
or presence of di¡erent concentrations of monosaccharides: Man-6-
P (b) ; glucose-6-phosphate (8) ; mannose (a) ; galactose-6-sulfate
(O) ; mannose-1-phosphate (l) ; galactose-6-phosphate (F) ; and
galactose (E).
Fig. 2. Binding of 125I-PSP-II to glycoproteins coated onto plastic
microwells. Glycoproteins were coated at di¡erent concentrations
onto microwells. Acid-hydrolysed CPY (F) ; native CPY (E) ; and
other glycoproteins (8) including acid-treated and native invertase,
ribonuclease B, and the native and desialylated forms of ¢brinogen,
transferrin, fetuin and PDC-109. Inset: E¡ect of alkaline phospha-
tase digestion of hydrolysed CPY on the binding of 125-I-PSP-II.
Wells coated with hydrolysed CPY were treated with 30 U/ml alka-
line phosphatase in Tris bu¡er, pH 9.5, for 2 h (O) or 24 h (R),
prior to the incubation with 125I-PSP-II. Hydrolyzed CPY-coated
wells incubated with the same bu¡er for 24 h (F) were used as con-
trol.
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tures common to sugar-binding sites in a number of plant and
animal lectins, i.e. van der Waals packing of a hydrophobic
sugar face against an aromatic amino acid side chain and
hydrogen bonding to the sugar hydroxyl groups [24], and
the requirement of a suitable counter-ligand for the charged
phosphate group, we have explored possible binding sites for
Man-6-P on the PSP-II crystal structure [25,26]. Only one
plausible site was found located at a shallow groove at the
interface with PSP-I. Man-6-P could be docked into this site
with the hydrophobic face of the sugar ring making stacking
interaction with the aromatic ring of Tyr108 (Fig. 4). This
model is characterized by hydrogen bonds between Man
HO-4 and the OQ of Ser100 (3.05 Aî ) and between Man HO-
4 and Man HO-3 and the carbonyl oxygen atom of Gly109
(3.09 Aî and 3.08 Aî , respectively). In addition, the NO group of
Arg43 is involved in two salt bridges with O1 and O2 of the
phosphate group of Man-6-P (3.17 Aî and 3.42 Aî , respectively)
and Man-6-P HO-1 interacts with the NH1 group of Arg43
through another salt bridge (3.23 Aî ).
On the basis of polar interactions and maximum surface
complementarity between the heparin tetrasaccharide
GlcA(2-O-SO3)-GlcNSO3(6-O-SO3)IduA(2-O-SO3)-GlcNSO-
3(6-O-SO3) [27] and PSP-II, two possible heparin binding re-
gions, both located in the proximity of the proposed Man-6-P
recognition site, were predicted by molecular modelling. The
¢rst region extends from Arg43 towards Arg2 and the surface
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Fig. 5. Proposed docking site for a heparin tetrasaccharide on PSP-II. The molecular surface of PSP-II is colour-coded by electrostatic potential
from negative (red) to positive (blue). The ¢gure was rendered with GRASP [36].
Fig. 4. Docking of mannose-6-phosphate onto the PSP-II structure.
Connolly surface of the proposed complex between mannose-6-phos-
phate and PSP-II showing the hydrogen bonding network. For
clarity, only PSP-II residues proposed to be directly involved in the
binding are shown in ball-and-stick mode. Hydrogen bonds are rep-
resented by white dashed lines. The plot was made with TURBO-
FRODO [35].
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area hidden upon docking of the tetrasaccharide onto PSP-II
is 300 Aî 2. The second, and most favoured region, extends
from Arg43 towards Lys37, on the opposite side of the PSP-
II molecule. The binding interface shows a remarkable com-
plementarity in the energy-minimised complex, rising up to a
contact area of 450 Aî 2 (Fig. 5). In the latter model, the hep-
arin tetrasaccharide was accommodated into this region mak-
ing several favourable contacts with the protein. The GlcA 2-
O-sulfate interacts with the NH1 and NH2 groups of Arg43
(3.34 Aî and 2.77 Aî , respectively). The 6-O-sulfate of the in-
ternal glucosamine makes contact (2.98 Aî ) with the OQ of
Ser17, and the N-sulfate of the reducing GlcN interacts with
the NZ group of Lys37 (3.17 Aî ). Furthermore, the IduA car-
boxyl group could be involved in a water-mediated contact
with Gln40. Thus, the four sugar residues would be involved in
the binding. The bound tetrasaccharide lies in line with the
Man-6-P binding site, the two sites extending towards oppo-
site sides of Arg43.
4. Discussion
Binding studies using immobilised polysaccharides showed
that iodinated PSP-II shares with other spermadhesin mole-
cules binding speci¢city towards heparin and fucoidan. This
binding activity appeared not to be merely related to the
charge density of the polysaccharides. Thus, heparin and fu-
coidan, with charge densities per monomer of 31.9 and 30.3,
respectively [28], were bound with similar avidity by PSP-II,
while chondroitin-sulfate, with a charge density of 31.0, did
not interact with PSP-II. Furthermore, binding of 125I-PSP-II
to heparin was inhibited by galactose-6-phosphate or man-
nose-1-phosphate and not by glucose-6-phosphate or Man-6-
P. Thus, although apparently considerable variability in the
saccharide structure (heparin vs. fucoidan) can be tolerated,
the results suggest that there must be some structural and/or
conformational requirements for sulfated glycan binding to
PSP-II.
In addition to sulfated polysaccharides, the results revealed
a novel binding capability for a spermadhesin molecule to-
wards phosphomannose oligosaccharides. Hence, PSP-II did
not interact with noticeable avidity with glycoproteins like
(asialo)fetuin and PDC-109, which are good ligands of sper-
madhesins AWN, AQN-1, and AQN-3 [29,30], but bound to
zymosan and to mild acid hydrolysed CPY. However, PSP-II
did bind neither to CPY prior to the hydrolysis treatment nor
to the same glycoprotein after alkaline phosphatase digestion.
These results suggested that PSP-II bound to exposed Man-6-
P monoester groups but not to the ‘capped’ phosphodiesters
present in native CPY. Furthermore, the binding of PSP-II to
hydrolysed CPY was selectively inhibited, although at milli-
molar concentrations, by Man-6-P and glucose-6-phosphate
but not by other neutral and acidic monosaccharides, evidenc-
ing that the binding was speci¢c and not only related to the
acidic nature of the saccharide. On the other hand, no binding
of PSP-II to either native or acid-treated invertase, a protein
containing phosphomannosyl residues was detected. This
strongly argues that beyond the recognition of the Man-6-P
epitope, PSP-II may display a ¢ne speci¢city in its binding of
Man-6-P containing oligosaccharides.
PSP-II did not bind to any of the phospholipids tested,
indicating that the binding activity displayed by PSP-II to-
wards phosphorylated sugars was not related to the phospho-
lipid binding activity exhibited by sperm-coating seminal plas-
ma proteins like boar spermadhesins AWN-1 and AQN-3,
which display a⁄nity for phosphorylethanolamine [31] and
PDC-109, a bovine phosphorylcholine-binding protein [21^
23].
Recognition of Man-6-P by PSP-II was also clearly distin-
guishable from the binding of sulfated polysaccharides, as
evidenced by the sharply di¡erent inhibitory activities exerted
by acidic monosaccharides. The most potent inhibitors of the
binding of PSP-II to acid-treated CPY are almost inactive on
the binding to heparin, and vice versa. Heparin exerts a par-
tial inhibition of PSP-II binding to hydrolysed CPY, however,
suggesting that the corresponding binding sites may overlap
or be in close spatial proximity. The location of these binding
sites at the region of PSP-II involved in heterodimer forma-
tion with PSP-I was suggested by the fact that the PSP-I/PSP-
II heterodimer displayed neither heparin nor phosphoman-
nose binding activities. Furthermore, binding of PSP-II to
mild acid hydrolysed CPY was completely inhibited in the
presence of the PSP-I subunit. The ability of PSP-II and
PSP-I to fully reassociate into a heterodimer strongly indi-
cated that the inhibitory activity of PSP-I may be linked to
reconstitution of the heterodimer, which may sterically block
the Man-6-P and the heparin binding sites. Indeed, docking of
Man-6-P onto the recently solved crystal structure of the PSP-
I/PSP-II heterodimer [25,26] suggested that the most plausible
binding sites for Man-6-P and heparin are located at the inter-
face of PSP-II with PSP-I.
The proposed Man-6-P binding site involves a number of
favourable contacts between the hydroxyl groups of the sac-
charide and protein main- and side-chain groups, which fully
satisfy the experimental binding speci¢city. Binding of man-
nose but not of galactose to PSP-II might be explained by the
involvement of the hydroxyl group at position 4 in a contact
with Ser110. On the other hand, the HO-2 group does not
make any contact with the protein, in agreement with results
showing similar a⁄nity of PSP-II for Man-6-P and glucose-6-
phosphate.
A binding site for heparin, also partly buried in the hetero-
dimer interface, is proposed on the basis of the high comple-
mentarity with a tetrasaccharide fragment of heparin. The
proposed heparin-binding site is contiguous to, and aligns
with the Man-6-P recognition site, and, like the latter, impli-
cates Arg43. This residue also plays a role in the stabilisation
of the heterodimeric association between PSP-II and PSP-I
[25,26] by formation of a salt bridge with PSP-I Glu104, and
by means of water-mediated hydrogen bond interactions with
Tyr17 and Thr19 of PSP-I. Thus, Arg43 emerges as a key res-
idue in both ligand binding and heterodimer formation.
The participation of PSP-I/PSP-II in the fertilisation proc-
ess remains enigmatic. The fact that both PSP-II heparin and
Man-6-P binding activities are cryptic in the PSP-I/PSP-II
heterodimer raises the question of their possible biological
signi¢cance. The presence of cryptic binding sites which are
exposed by di¡erent stimuli has been proposed for a number
of heparin-binding proteins. For instance, denaturation/multi-
merisation of plasma vitronectin exposes heparin-binding sites
which are also physiologically inducible by glycosaminoglycan
binding or by incorporation into the terminal complement
complex [32,33]. Furthermore, a cryptic Man-6-P binding ac-
tivity has been described in a cell surface lectin from Giardia
lamblia [34], a human protozoan parasite that causes diar-
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rhoeal disease. This lectin is speci¢cally activated by a host
protease, trypsin, which is secreted in vivo at the site of in-
fection, suggesting that the lectin may contribute to the host-
parasite interaction. The possibility that cryptic binding sites
in the PSP-I/PSP-II heterodimer could be exposed in response
to a speci¢c physiological environment cannot be ruled out
and deserves further investigation.
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